“Dapagliflozin and Urinary Tract Infection Risk in Type 2 Diabetes: A Comprehensive Critical Review of Mechanistic, Randomized, and Real-World Evidence” (2026) Tropical Journal of Pharmaceutical and Life Sciences, 13(5), pp. 53–68. doi:10.61280/9h681f91.